Clinical Trial Update: Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sintilimab plus bevacizumab as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after curative resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: HCC, Adjuvant Therapy | Phase 3 | Status: UNKNOWN